Andria Rae Crisler

In Fish & Richardson’s 2025 biologics and biosimilars review, we cover Food and Drug Administration (FDA) approvals, new biosimilar launches, Biologics Price Competition and Innovation Act (BPCIA) litigation and other litigation implicating biologics, post-grant challenges against biologic patents, and biologics-related legislative and regulatory developments from 2025. The U.S. biosimilars market continued its rapid growth in 2025.

In Fish & Richardson's 2025 biologics and biosimilars review, we cover Food and Drug Administration (FDA) approvals, new biosimilar launches, Biologics Price Competition and Innovation Act (BPCIA) litigation and other litigation implicating...

The August 2025 edition of our Texas Round-Up focuses on developments in cases involving pharmaceutical and medical device products. On August 8, 2025, Judge Payne granted Sun’s request to transfer Nivagen’s case against it from the Eastern District of Texas to the District of New Jersey. Nivagen’s complaint alleges infringement by Sun’s product, SEZABY™ (phenobarbital sodium), indicated for the treatment of neonatal seizures in term and preterm infants.